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1. Introduction 
Contrast-induced nephropathy (CIN) is an injury to the kidney as a result of exposure to 
intravascular iodinated contrast medium. It represents an increasing health care burden and 
challenge as the frequency of diagnostic imaging and interventional studies increase, 
particularly among populations at risk of developing CIN. As the population ages, 
decreased renal function and increased atherosclerotic cardiovascular disease become more 
prevalent. An increasing incidence of obesity with resultant metabolic syndrome and/or 
type 2 diabetes mellitus also increases the population at risk for CIN (Toprak et al., 2006). 
Coronary artery disease is a major complication of type 2 diabetes mellitus. Thus, patients 
with type 2 diabetes mellitus often require coronary angiography and coronary intervention 
and are at risk of CIN.  
2. Contrast-induced nephropathy in patients with type 2 diabetes mellitus 
and coronary artery disease 
For clinical and research purposes, CIN is defined as an acute decline in renal function (rise 
in serum creatinine by 25% or greater than 0.5 mg/dL from baseline or fall in estimated 
glomerular filtration rate (eGFR) by greater than 25%) after systemic contrast medium 
administration in the absence of other causes. Typically, CIN onset occurs within 24-48 
hours of exposure, serum creatinine levels peak in 3-5 days, and renal function returns to 
baseline in 7-21 days. If renal function does not return to baseline, other causes of acute 
renal injury, like atheroembolism or hypotension, should be suspected (Saleem et al., 1996). 
CIN is associated with both short-and long-term adverse outcomes, including the need for 
renal replacement therapy, increased length of hospital stay, major cardiac adverse events, 
and mortality. The incidence of CIN is less than 5% in patients with normal renal function 
and 15-50% in patients with baseline renal dysfunction (eGFR less than 60 mL/min/1.73m2). 
The increased risk of CIN in diabetic patients with reduced renal function is well 
documented (Parfrey et al., 1989). Yet, diabetic patients without overt renal dysfunction are 
also at risk as compromised renal function may not manifest until an acute renal insult 
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results from the administration of contrast medium. CIN carries short-term and long-term 
mortality. Acute renal failure after coronary intervention is associated with a 36% in-
hospital mortality rate and a 19% 2-year survival rate. Thus, understanding why patients 
with type 2 diabetes are at increased risk of CIN and controlling factors to decrease the risk 
of CIN, has major short- and long-term benefits to patients with type 2 diabetes (Nikolsky et 
al., 2004). Most clinical studies on CIN have mainly been in patients with type 2 diabetes 
mellitus rather than type 1 diabetes mellitus and, thus, the remarks in this chapter will be 
confined to patients with type 2 diabetes kidney disease.  
2.1 Mechanisms of contrast-induced nephropathy in patients with type 2 diabetes 
mellitus 
The pathogenesis of CIN is complex with a cascade of contributing factors that are not fully 
understood. Factors contributing to CIN in patients with type 2 diabetes mellitus include 
decreased GFR, endothelial dysfunction and increased reactivity to intrarenal adenosine 
(Pfueger et al., 2000). After injection of contrast medium, renal blood flow increases 
transiently, followed by a more prolonged decrease, particularly at the corticomedullary 
junction of the kidney. The outer medulla is particularly susceptible to ischemic injury 
because of its high metabolic activity and low prevailing oxygen tension. Associated with 
the decrease in renal blood flow, there is a decrease in glomerular filtration rate due to 
afferent renal arteriolar vasoconstriction which is calcium-dependent with increased 
intrarenal adenosine and increased endothelin-1 activity as likely mediators of the 
vasoconstriction (Arakawa et al., 1996). The risk of CIN increases if there are inadequate 
compensatory vasodilatory responses, such as prostaglandins (E2 and I2) and nitric oxide.  
Renal tubular cellular injury, in part, is mediated by generation of oxygen-free radicals. 
Intrarenal adenosine accumulates due to the depletion of adenosine triphosphate as a 
consequence of proximal tubular stress due to osmotic load and the large size of contrast 
media molecules. The renal toxicity from the direct effects of contrast media is reversible. It 
has been shown in vitro that renal tubular cells respond to contrast media exposure by 
increasing the concentrations of extracellular adenosine and by decreasing the activity of 
mitochondrial enzymes without altering viability. A late effect of intrarenal adenosine is 
oxygen-free radical production due to the catabolism of intrarenal adenosine to xanthine.   
A role for intrarenal adenosine as a renal vasoconstrictor and substrate for oxygen-free 
radical formation is supported in human studies. Adenosine increases in urine following 
contrast medium; the magnitude of adenosine release and depression of creatinine clearance 
is proportional to the osmolality of the contrast agent, essentially a dose response 
relationship. Further, an inhibitor of adenosine uptake, dipyridamole, exacerbates the fall in 
GFR after contrast medium. In addition, blockade of the renal arterial adenosine receptors 
with theophylline attenuates the fall in GFR following contrast medium. Finally, following 
pretreatment with allopurinol (a xanthine oxidase inhibitor), urinary xanthine increases and 
the fall in GFR after contrast medium is lessened.  
Endothelin is a potent renal afferent arteriolar vasoconstrictor, like intrarenal adenosine. 
Intravascular administration of contrast medium induces exacerbated release of urinary 
endothelin in patients with impaired renal function. Human studies show no significant 
increase in plasma endothelin levels until a volume of contrast media administered is 
greater than 150 mL (Clark et al., 1997). However, in diabetic patients or in patients with 
renal insufficiency, significant endothelin levels are detected when less than 100 mL of 
contrast medium are administered intraarterially.  
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In patients with normal GFR, the risk of CIN is likely less, not only because of more rapid 
clearance of contrast medium from the kidney (less time for generation of oxygen-free 
radicals), but, presumably, because of the presence of a variety of endogenous vasodilators 
that protect against renal ischemia, including prostaglandins (E2 and I2), atrial natriuretic 
peptide and nitric oxide. In patients with GFR of less than 60 mL/min/1.73 m2, the risk of 
CIN increases with prolonged clearance of contrast medium.  
In summary, patients with type 2 diabetes mellitus appear to be at increased risk of CIN, not 
only because chronic renal disease is common in these patients, but also because there 
appears to be a greater vasoconstriction of the renal afferent arterioles to intrarenal 
adenosine and suppressed nitric oxide bioavailability in the kidney due to endothelial 
dysfunction (Komers & Anderson, 2003). Recent reports indicate that severe renal 
dysfunction need not be present to create a risk of CIN in diabetic patients with measured 
creatinine clearance of 100 mL/min and receiving proper hydration (Hardiek et al., 2008).  
2.1.1 Prevention strategies to attenuate contrast-induced nephropathy in patients with 
type 2 diabetes mellitus and coronary artery disease 
Since treatment of CIN after it has occurred is ineffective, efforts to prevent or attenuate the 
injury are the focus of ongoing investigations. Early diagnosis and careful long-term 
treatment of patients with type 2 diabetes mellitus and coronary artery disease includes 81 
mg aspirin daily, angiotensin-converting enzyme inhibitor therapy or angiotensin II 
receptor blocker therapy and 3-hydroxyl-methylglutaryal coenzyme A reductase inhibitor 
therapy. Ideal goals for vascular risk factor modification include blood pressure of 130/80 
mmHg or better, LDL cholesterol less than 70 mg/dL and hemoglobin A1C less than 7%. 
Successful accomplishment of these goals should decrease the progression of macro- and 
microvascular complications. In addition, if these goals are accomplished, endothelial 
function should be better.  If the patient suddenly develops an acute coronary syndrome, the 
ability of the kidney to have a compensatory vasodilatory response in response to contrast 
medium should decrease the risk of CIN. Based on the assumption that acute renal 
adenosine and/or endothelia-medicated vasoconstriction and endothelial dysfunction are 
major interrelated pathogenic events in CIN, a type 2 diabetic patient meeting therapeutic 
goals should be at lower risk when coronary angiography and/or coronary intervention are 
required. When a patient with type 2 diabetes presents with an acute coronary syndrome, 
hyperglycemia is common, and increased risk of mortality in patients has been observed 
(Kosiborod & McGuire, 2010). Well-designed, large clinical outcome trials are required for 
better guidance as far as how hyperglycemia in the acute situation should be managed. 
Observational studies suggest that hypoglycemia should be avoided (Zoungas et al., 2010). 
Guidelines now recommend a therapeutic target of glucose control at 140 to 180 mg/dL in 
the critically ill patient which is a more liberal approach than prior recommendations 
(O’Keefe et al., 2011). Previously recommended more aggressive glucose lowering 
(including normalization of blood sugar) was not shown to have additional benefit and 
appeared to be harmful because of the increased incidence of hypoglycemia.  
As mechanisms for CIN in patients with type 2 diabetes mellitus are better understood, 
there is a growing list of medications that may exacerbate the risk of CIN. Many of these 
medications are taken by patients with cardiovascular disease and should be addressed 
prior to proceeding with angiography. Medications that increase the risk of a patient 
developing CIN include nonsteroidal anti-inflammatory drugs which inhibit compensatory 
renal prostaglandin synthesis, diuretics that dehydrate the kidney and increase the risk of 
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medullary ischemia, and dipyridamole that blocks the normal cellular uptake of adenosine 
resulting in a greater renal adenosine – mediated vasconstrictive response.  
In patients with type 2 diabetes mellitus requiring elective angiography, nonsteroidal anti-
inflammatory medicines, diuretics and dipyridamole should be held prior to the procedure. 
While nonsteroidal anti-inflammatory medications are considered the cornerstone for 
managing the pain of osteoarthritis and other painful conditions, recent meta-analysis 
indicate significantly increased risk of myocardial infarction, stroke or death from 
cardiovascular disease compared to placebo with the chronic use of these medications. 
Contrary to some previous reports, the current meta-analysis found no suggestion that this 
increased cardiovascular risk is specific to cyclo-oxygenase-2 inhibitors. Data were available 
for naproxen, ibuprofen, diclofenac, celecoxib, etoricoxib, rofecoxib and lumiracoxib. 
Overall, naproxen appeared to be the least harmful nonsteroidal anti-inflammatory 
medication in terms of cardiovascular outcomes. Risks were greatest with ibuprofen, 
diclofenac, etoricoxib and lumiracoxib. Thus, chronic use of nonsteroidal anti-inflammatory 
medications in patients with type 2 diabetes who are at increased cardiovascular risk is 
discouraged. In regard to dipyridamole, recent data suggests superiority of clopidogrel over 
dipyridamole in patients who have suffered a cerebral vascular accident. Increasingly 
clopidogrel rather than dipyridamole is the recommended antiplatelet agent in addition to 
81 mg aspirin in patients with type 2 diabetes after transient ischemic attacks or cerebral 
vascular accidents. Thus, if the patient with type 2 diabetes mellitus needs emergency 
angiography, the risk of dipyridamole contributing to CIN would no longer exist. 
Patients with type 2 diabetes mellitus have a significantly greater risk of macrovascular 
disease, including coronary heart disease, stroke and peripheral vascular disease, in addition 
to the microvascular complications, such as retinopathy, neuropathy and nephropathy. 
Despite evidence of benefit for reduction of microvascular disease with glycemic control, to 
date, there is no such evidence for the role of glycemic control in macrovascular event 
reduction. In newly diagnosed patients with type 2 diabetes, besides initiation of diet, exercise 
and weight reduction, metformin is usually the recommended initial therapy unless 
contraindicated, such as renal disease (serum creatinine greater than 1.5 mg/dL in males and 
greater than 1.4 mg/dL in females). Although not relevant to CIN prevention, metformin 
should be temporarily discontinued at the time of or prior to use of contrast medium or major 
surgical procedures and withheld for 48 hours after the procedure. Metformin should be 
restarted after renal function has been reevaluated and found to be normal (Goergen et al., 
2010). While the mortality rate for patients who develop lactic acidosis can be quite high, the 
actual number of people dying from metformin-induced lactic acidosis after contrast medium 
exposure is quite low using these guidelines.  
Cigarette smoking is the most common cause of preventable morbidity and mortality in 
developed countries. In addition to it being a major risk factor for cardiovascular disease, 
lung disease and cancer, cigarette smoking is now recognized as an important independent 
risk factor of chronic kidney disease, including diabetic nephropathy, by increasing the rate 
of transition from microalbuminuria to proteinuria and promoting the progression to end-
stage renal disease (Phisitkul et al., 2008). Furthermore, a recent cross-sectional analysis of 
participants in the National Health and Nutrition Examination Survey demonstrated a 
strong association between exposure to secondhand smoke and proteinuria, suggesting that 
passive smokers are also at increased risk of chronic kidney disease (Obert et al., 2011). 
Several clinical and experimental studies have demonstrated the role of transforming 
growth factor-beta in the pathogenesis of chronic kidney disease, including diabetic 
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nephropathy. This cytokine is largely profibrotic and plays a significant role in diabetic 
nephropathy by increasing the production of extracellular matrix proteins, including 
fibronectin and collagen, in the glomerulus. It is also known that one cigarette paralyzes the 
ability of the endothelium to make nitric oxide for up to 24 hours. Thus, patients with type 2 
diabetes mellitus should be counseled to discontinue smoking. Emphasizing that 
recommendation prior to elective angiography may decrease the incidence of CIN. 
Another class of medication that warrants discussion in the long-term treatment of patients 
with type 2 diabetes mellitus, not only for the long-term metabolic advantages, but also 
because of the risk of CIN is beta-blocker therapy. Both nonselective and selective 
traditional beta-blockers have been shown to increase insulin resistance, facilitate weight 
gain of approximately 1 kilogram per six months and worsen hypertriglyceridemia by 
approximately 13%. In contrast, carvedilol in hypertensive diabetic patients has been found 
to have a neutral effect on insulin resistance, weight and triglycerides (Bakris et al., 2004). 
This favorable metabolic profile also suggests that carvedilol is a better choice compared to 
traditional beta-blockers in these high risk patients. Recent trials emphasize the class 
heterogeneity that exists for beta-blockers and provide a strong basis for preferred use of 
carvedilol in patients with type 2 diabetes. Carvedilol is a unique molecule that combines 
the properties of a nonspecific beta-blocker and a specific alpha-1-blocker in a ratio of 2:3. 
Carvedilol also possesses antioxidant properties. In hypertensive diabetic patients, 
carvedilol compared to metoprolol tartrate has been shown to reduce existing 
microalbuminuria and to decrease the risk of progression to microalbuminuria. These 
results suggest improved endothelial function and may be related to improvement in insulin 
resistance or an effect on oxidant stress in the kidney. Thus, in patients with type 2 diabetes 
mellitus that require beta-blocker therapy, carvedilol has become the recommended beta-
blocker. There are also data to suggest that carvedilol compared to traditional beta-blockers 
attenuates CIN. Proposed mechanisms include unopposed alpha-medicated renal 
vasoconctriction causing more ischemia when on traditional beta-blockers and/or improved 
endothelial function due to the antioxidant properties of carvedilol. 
There are other medicines that may attenuate the risk of CIN. Calcium-channel blocking 
medications attenuate both the magnitude and duration of renal vasoconstriction after 
contrast medium administration (Russo et al., 1990). In patients with type 2 diabetes 
mellitus and hypertension and/or angina requiring calcium-channel blocking medications, 
these medications should be continued if contrast medium administration is planned.  
The adenosine receptor antagonists, theophylline and aminophylline, attenuate the decrease 
in GFR seen after contrast medium. Since patients with type 2 diabetes mellitus have an 
increased reactivity to intrarenal adenosine, theophylline prior to contrast medium 
administration warrants special consideration. The kidney responds to contrast media-
induced stress with a tubuloglomercular feedback response which is largely medicated by 
adenosine when less than 100 mL of contrast medium is administered. This mechanism has 
been confirmed by both animal and clinical studies. Pretreatment with long-acting 
theophylline 3 mg/kg orally at least 30 minutes before contrast medium administration and 
12 hours later in addition to hydration has been shown to attenuate the depression of 
creatinine clearance. It is critical that theophylline be administered before contrast medium 
injection, but prolonged treatment after angiography is unnecessary. Theophylline 
prophylaxis is effective, safe, and inexpensive. This dose of theophylline is manyfold greater 
than the minimum dose required to block renal vascular adenosine receptors and is well 
below that shown to affect renal cyclic nucleotide phosphodiesterase activity (Vassallo & 
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Lipsky, 1998). This dose of theophylline causes transient plasma theophylline levels of 7 
mcg/mL which is below therapeutic levels required for treatment of asthma and unlikely to 
cause serious gastrointestinal, neurological, or cardiovascular adverse effects (Cooling, 1993; 
Shannon, 1999). 
Adenosine receptor antagonists, theophylline and aminophylline, prophylaxis to attenuate 
CIN has not been strongly adopted except in patients at high risk for CIN. Some controlled 
trials have shown a significant reduction in the risk for CIN while others have shown no 
reduction (Abizaid et al., 1999; Erley et al., 1999; Erley et al., 1994; Gandhi et al., 1992; Huber 
et al., 2001; Huber et al., 2002; Huber et al., 2003; Kolonko et al., 1998; Shammas et al., 2001). 
However, these studies have been limited by small sample size, variation in timing and 
dosage of drug administration, and variation in the definition of CIN. Three meta-analyses 
have dealt specifically with the clinical use of theophylline for the prevention of CIN. Each 
of these gave extensive information concerning the way that the papers which were 
included were chosen, exactly what factors were chosen for matching across studies and 
which factors did not match. In addition, statistics were presented which addressed the 
concerns about selection bias and efforts were made to adjust for non-matching factors to 
the extent possible. No attempt will be made to describe each of these studies completely, 
however, we will give some summary information concerning each of them. One meta-
analysis identified 10 studies in which theophylline was used for the prevention of CIN (Ix 
et al., 2004). Of the ten, seven were found to fulfill all the inclusion criteria and these 
constituted the final sample for the analysis. The studies included were reported between 
1994 and 2003 and included a number of different protocols for the administration of the 
theophylline. The final conclusion reached by these investigators was that the prophylactic 
administration of theophylline appears to protect against contrast-induced declines in 
kidney function. They also reported that “the protective benefits appeared robust regardless 
of the study design, form or volume of contrast medium delivered, and the presence or 
absence of intravenous volume expansion.” The investigators did indicate that they were 
unable to determine (given the available data) if theophylline reduced the number of 
patients who experienced large increases in serum creatinine concentrations or required 
dialysis. Another meta-analysis identified nine studies which met the study criteria for their 
protocol (Bagshaw & Ghali, 2005). Their conclusion was that the data they considered 
indicated that there is promising evidence supporting the use of theophylline for the 
prevention of CIN but the evidence is still not conclusive. They suggested that what was 
required to answer this question was a larger, well designed clinical trial for confirmation 
and assessment of risks before theophylline could be recommended routinely for the 
prevention of CIN. They also noted from their analysis of these papers that such a trial 
should include a hydration protocol and the routine use of low or iso-osmolar nonionic 
contrast media since those are now the current standards of care. These two meta-analyses 
focused primarily on theophylline and a comparison of the choices of papers from the two 
studies shows that seven papers included in the initial meta-analysis were also included in 
the nine chosen by the second meta-analysis. The latter authors included two papers which 
were in the same search time frame as the initial meta-analysis but were not selected under 
that study protocol. A third meta-analysis covered a number of drugs aimed at reducing the 
incidence of CIN (Kelly et al., 2008). The primary drug considered was N-acetylcysteine 
with theophylline being more secondary to the study. Only six of the studies considered 
dealt primarily with theophylline. Of the six considered, five were part of the set of studies 
considered by the second meta-analysis while four of them coincided with those used in the 
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initial meta-analysis. The sixth paper which was unique to this analysis appeared in 2006 
which was out of the range of years covered by the other two papers. One of the six papers 
common to both was not included by the initial meta-analysis. The conclusion of this paper 
with respect to the efficacy of theophylline was that it produced a large risk reduction but  
did not achieve statistical significance. Of these three meta-analyses, the first two are most 
comparable. Both reach the same conclusion. Each of these papers used slightly different 
statistical methods. Both contained a thorough discussion of the selection criteria used to 
choose the papers included and measures to check for selection bias. The general 
conclusions were favorable with the hypothesis that theophylline is protective against CIN. 
Unfortunately, neither group of authors was willing to report a definitive answer. There are 
some  areas where the studies under review by these authors differed. One was in the area 
of how the theophylline was administered: as a fixed dose regardless of body weight or as a 
dose adjusted per kilogram of body weight. The broad conclusion reached is that a large, 
carefully designed clinical trial needs to be conducted to reach a final conclusion. The trial 
should be stratified according to ancillary risk factors such as age and diabetes. In addition, 
the effect of the dosing protocol and hydration methods needs to be considered. Finally, 
since it is known that certain beverages like coffee and tea also block adenosine vascular 
receptors, a study testing the benefit of theophylline should exclude other xanthine 
exposure during the time before contrast medium administration and for the 48 hours after 
while the subject is being followed. 
Studies suggest two mechanisms by which intrarenal adenosine contributes to CIN. Early 
depression of renal function after contrast medium exposure is caused by A1 receptor-
mediated renal afferent arteriolar vasoconstriction and A2 receptor-mediated efferent 
arteriolar vasodilatation resulting in decreased glomerular perfusion pressure. Later 
depression of renal function after contrast medium exposure is caused by oxygen-free 
radical production, in part, due to intrarenal adenosine catabolism to xanthine.  
Pretreatment with theophylline may attenuate CIN by maintaining GFR such that contrast 
medium is cleared from the kidney more rapidly, thus, decreasing direct cytotoxic effects 
from contrast medium and decreasing the potential for intrarenal adenosine-mediated 
oxygen-free radical production. Pretreatment with allopurinol has also been shown to 
attenuate CIN. To be effective, it is crucial to administer allopurinol at least 24 hours prior to 
exposure to contrast medium. Pretreatment allows time for production of oxypurinol, the 
chief metabolite of allopurinol, which is a much more potent xanthine oxidase inhibitor. 
Allopurinol administered in this fashion was renally protective. Decreasing renal xanthine 
oxidase decreases the catabolism of intrarenal adenosine to xanthine resulting in decreased 
oxygen-free radical production and less renal tubular cell injury.  
Patients with type 2 diabetes mellitus are usually on angiotensin-converting enzyme 
inhibitors, angiotensin II receptor blockers and/or direct renin inhibitor to decrease the 
progression of renal disease. Whether these agents need to be held or should be continued 
when contrast medium is administered requires clinical judgment. Intrarenal angiotensin II 
enhances adenosine-mediated vasoconstriction so theoretically blockade of the renin-
angiotensin system should attenuate the risk of CIN. In support of this concept, 
preprocedure angiotensin-converting enzyme inhibitor use has been shown to lower the risk 
for CIN in patients with chronic renal disease (Dangas et al., 2005). Another clinical trial 
showed that periprocedural captopril, compared with an untreated control group, reduced 
the risk of CIN in patients with type 2 diabetes mellitus (Gupta et al, 1999). However, if an 
unstable patient has low cardiac output or hypotension, renin-angiotensin system blockade 
www.intechopen.com
 
Advances in the Diagnosis of Coronary Atherosclerosis 
 
242 
is known to worsen glomerular perfusion (i.e. intrarenal angiotensin II is needed). In such 
patients, angiotensin-converting inhibitor therapy has increased the risk of CIN (Cirit et al., 
2006; Holscher et al., 2008; Louis et al., 1996; Rosenstock et al., 2008). Given the long-term 
benefit of angiotensin-converting enzyme inhibitor and angiotensin II receptor antagonists, 
most believe these medications should be continued in patients with diabetes mellitus and 
chronic kidney disease requiring contrast medium administration unless the patient is 
hemodynamically unstable. However, if angiotensin-converting enzyme inhibitors or 
angiotensin II receptor blockers are held before contrast medium administration, they 
should be restarted when renal function is considered stable. 
Recent research suggests that 3-hydroxy-methylglutaryl coenzyme A reductase inhibitors, 
or statins, may reduce the risk of CIN because they have beneficial effects on endothelial 
function, maintain nitric oxide production and reduce oxidative stress (Adel et al., 2010). 
Recent retrospective reviews of patients with renal impairment undergoing angiography 
suggests that the risk of CIN was lower in patients in whom a statin was initiated before the 
procedure (Khanal et al., 2005). These findings reinforce the rationale for the introduction of 
statin therapy before undergoing diagnostic or interventional coronary angiography, 
particularly in patients with type 2 diabetes mellitus (Attallah et al., 2004).  
Hypomagnesemia, serum magnesium level less than 2 mEq/L, may also be a correctable 
risk factor for CIN in patients with renal dysfunction. Patients with type 2 diabetes mellitus 
frequently become hypomagnesemic due to poor control with glycosuria, the development 
of an acquired renal tubular defect and from chronic diuretic therapy. All three conditions 
decrease the renal tubular reabsorption of magnesium. Detecting hypomagnesemia and 
correcting it prior to angiography or coronary intervention may be indicated. The renal 
protective effect of magnesium is likely multifactorial. Besides its role as an antioxidant and 
as a coenzyme for compensatory sodium-potassium adenosine triphosphatase, magnesium 
has calcium channel blocking properties.  
The universally accepted prevention strategy for CIN is adequate intravenous volume 
expansion. Extracellular volume expansion plays a well established role in reducing the risk 
of CIN although few trials have directly addressed the ideal protocol. Intravenous volume 
expansion before and after the administration of contrast medium appears to be more 
effective than either bolus volume expansion during the procedure or removal of 
restrictions on oral fluid intake. Isotonic saline has been found to be better than 0.45% saline 
and is given intravenously before and after administration of contrast medium for a total of 
24 hours. An additional strategy that is under study is for patients to receive prophylactic 
volume expansion with isotonic sodium bicarbonate solution (Merten et al., 2004). It is 
thought that an alkaline environment decreases oxygen-free radical formation in the renal 
tubule. The findings of several recent trials and a meta-analysis indicate that volume 
expansion with sodium bicarbonate is more effective than volume expansion with saline. 
However, recent reports argue against a clear benefit for sodium bicarbonate volume 
expansion but examination of the various trials suggests that the dose given to accomplish 
an alkaline environment in the renal tubule is important. Isotonic sodium bicarbonate 
solution, administered at 3 mL/kg/h for one hour prior to angiography and at 1 mL/kg/h 
for, at least, six hours afterward accomplishes that goal. A major robust, well-designed trial 
comparing volume expansion with sodium bicarbonate versus normal saline is ongoing. At 
this time, the CIN consensus working panel concludes that no adjunctive medical 
pretreatment has been validated as effective for preventing CIN. Use of furosemide, 
mannitol or an endothelin receptor antagonist is potentially detrimental. Felodipine, 
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dopamine, atrial natriuretic peptide and L-arginine have not been shown to be effective. 
Potentially beneficial strategies for attenuating CIN include theophylline, allopurinol, 
ascorbic acid, oral and intravenous N–acetylcysteine, hemodialysis of contrast medium and 
venous capture of contrast medium.  
In regard to pretreatment approaches to limit oxygen-free radical injury following contrast 
medium, four pharmacologic approaches warrant further study with adequately powered, 
appropriately designed, randomized trials of high-risk diabetic patients, perhaps combined 
with theophylline pretreatment. One of these is isotonic sodium bicarbonate solution with 
the length of post-procedure treatment determined by the volume of contrast medium 
administered. Maintaining an alkaline environment should decrease oxygen-free radical 
formation in the renal tubule. As discussed above, one source of oxygen-free radical 
production after contrast medium is the catabolism of intrarenal adenosine to xanthine. 
Allopurinol, a xanthine oxidase inhibitor, 4 mg/kg orally daily starting 24 hours before 
administration of contrast medium has shown benefit. This dose of allopurinol, if given 24 
hours before elective procedures, is metabolized into oxypurinol which is a more effective 
xanthine oxidase inhibitor than allopurinol. This 24-hour pretreatment approach has been 
shown to attenuate the fall in GFR after contrast medium exposure. Besides limiting oxygen-
free radical formation, allopurinol may also protect the kidney from contrast medium 
exposure by its ability to inhibit adenine nucleotide degradation (thus, preservation of 
adenine nucleotide is required for recovery from renal injury). Allopurinol has also been 
found to markedly decrease the vasodilatation response to intravenous adenosine in the 
renal vasculature. Less adenosine-mediated efferent renal arteriolar vasodilatation would 
preserve glomerular perfusion pressure. In view of the possible role of oxidase stress and 
oxygen-free radical generation in CIN, ascorbic acid as an antioxidant warrants further 
study (Spargias et al., 2004). N-acetylcysteine, as an antioxidant and renal vasodilator, has 
not been shown to be consistently effective when given orally (Solomon, 2009). Perhaps a 
larger oral dose is needed or intravenous administration may be required. Allopurinol, 
ascorbic acid and N-acetylcysteine, if proven beneficial, require pretreatment and would be 
less helpful in diabetic patients requiring emergency diagnostic and/or interventional 
contrast medium usage. 
To decrease the risk of CIN requires careful patient screening and selection, adequate 
patient hydration, limiting the volume of contrast medium administered and choosing a 
safe, non-ionic, low osmolar contrast agent. Based on comparisons of contrast media in 
proximal renal tubular cell culture and in recent robust head-to-head prospective clinical 
trials in high risk patients, however, iso-osmolar iodixanol and low-osmolar iopamidol are 
comparable and appear to be the contrast agents of choice to reduce renal risk for CIN.  
The direct cellular toxicities of commonly used contrast medium have been compared in 
renal proximal tubular cells in culture (Hardiek et al., 2001). All contrast media, whether 
high-osmolar or iso-osmolar, ionic or non-ionic, stress renal proximal tubular cells. When 
renal proximal tubular cells in culture are exposed to contrast media, they respond by 
increasing extracellular adenosine concentrations because of the depletion of adenosine 
triphosphate due to osmotic load and the large size of contrast medium molecules. The renal 
toxicity from the direct effects of contrast medium is reversible, as has been shown in vitro in 
studies in which renal tubular cells respond to contrast media exposure by decreasing the 
activity of mitochondrial enzymes without altering viability. While all contrast medium may 
reduce mitochondrial enzyme activity, differences among agents are seen with iopamidol 
and iodixanol being the least toxic and the two ionic contrast media, ioxaglate and 
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diatrizoate, being the most toxic. The lesser the depression of mitochondrial function, the 
more rapidly renal proximal tubular cells can recover after contrast medium has been 
eliminated from the kidney suggesting that iopamidol and iodixanol are the least 
nephrotoxic molecules when studied in cell culture.  
Earlier clinical trials comparing contrast medium risk in patients with type 2 diabetes for 
CIN had limitations that prevented valid conclusions: the studies were not blinded, the 
number of patients was small, the timing of outcome assessment was unclear, or the patients 
received contrast intra-arterially and/or intravenously. With proper hydration and 
identification of high-risk patients, the incidence of CIN after intra-arterial contrast medium 
administration is about 10%. More recent trials in high-risk diabetic patients given contrast 
medium intravenously suggest that the incidence of CIN is about 5%. More recent trials 
have been head-to-head, robust and prospective in high-risk patients with chronic renal 
failure (eGFR 59-20 mL/min) with intra-arterial contrast medium administration. Based on 
animal studies, concern about osmotoxicity in the pathogenesis of CIN emerged which led 
to the development of low-osmolar, and, later, iso-osmolar contrast medium. Of interest, in 
human prospective trials and meta-analysis, no specifically significant differences in 
nephrotoxicity between high-osmolar (1,400-2,000 mOsm/kg) and non-ionic low-osmolar 
(600-800 mOsm/kg) contrast have been found in patients with normal renal function 
(Solomon, 2005). Clinical trials published in the 1990s, however, showed that use of high-
osmolar ionic monomer diatrizoate in patients with chronic renal disease who were 
undergoing coronary angiography had a higher incidence of CIN than that associated with 
non-ionic low-osmolar contrast medium. In general, lower osmolar contrast medium has 
now replaced diatrizoate for routine clinical use. It is less clear whether there are 
appreciable differences among various non-ionic low-osmolar contrast medium regarding 
the incidence of CIN. Because individual contrast medium has specific effects on renal 
tubular cells, head-to-head studies are required to compare the safer contrast medium in at 
risk patients undergoing angiography. With the development of the non-ionic iso-osmolar 
dimer, iodixanol, subsequent studies have evaluated whether a further reduction in 
osmolality would result in still more protection against CIN. In the first of these 
comparative studies ((Nephrotoxicity of High-Risk Patient Study of Iso-osmolar and Low-
Osmolar Non-ionic Contrast Medium (NEPHRIC)) 129 patients with diabetes with chronic 
renal failure (baseline eGFR of 48 mL/min) and serum creatinine levels 1.5-3.5 mg/dL were 
randomized to the low-osmolar contrast medium iohexol or the iso-osmolar contrast 
medium, iodixanol (Aspelin et al., 2003). A higher rate of CIN defined as a serum creatinine 
rise of greater than 0.5 mg/dL after angiography was noted after iohexol (26.2%) than after 
iodixanol (3.1%).  
Since the publication of NEPHRIC, subsequent prospective randomized trials involving 
high-risk patients with renal insufficiency and diabetes and the intra-arterial administration 
of contrast medium have not consistently found a lower incidence of CIN associated with 
iso-osmolar contrast medium. In general, a benefit favoring the non-ionic iso-osmolar dimer, 
iodixanol, is seen compared with the non-ionic low-osmolar monomer iohexol or the ionic 
low-osmolar dimer, ioxaglate. In contrast, when comparing non-ionic low-osmolar 
monomers, iopamidol or ioversol, in high-risk patients with iso-osmolar iodixanol, no 
additional protective effect is seen. There have been no head-to-head comparisons of iohexol 
with any other non-ionic, low-osmolar contrast agents in high-risk patients undergoing 
intra-arterial administration of contrast. Based on a recent systematic review of 
angiographic contrast medium in high-risk patients, however, the likely explanation of the 
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NEPHRIC findings is that low-osmolar, iohexol, appears to be more nephrotoxic than other 
low-osmolar contrast media, such as iopamidol and ioversol. Furthermore, a systematic 
review of angiographic contrast media in high-risk patients found no statistically significant 
difference in the risk of CIN between low-osmolar iopamidol and iso-osmolar iodixanol 
(Solomon, 2005). These comparisons in low-osmolar and iso-osmolar contrast medium 
administered intra-arterially in high-risk patients suggest that each molecules safety must 
be based on robust clinical trials. These data also suggest that physical and/or chemical 
properties of each molecule, other than osmolarity, are implicated in the pathogenesis of 
CIN. Given this incidence of CIN, prospective randomized trials need larger patient 
populations to be properly powered to be certain of the conclusions. The recently published 
Cardiac Angiography in Renally-Impaired Patients (CARE) study fits these criteria by being 
a multicenter, double-blind, randomized study designed to prospectively compare the 
incidence of CIN after intra-arterial administration of low-osmolar iopamidol or iso-osmolar 
iodixanol in 414 patients with moderate to severe chronic kidney disease (eGFR of 20-59 
mL/min/1.73 m2) who underwent coronary angiography or percutaneous coronary 
intervention (Solomon et al., 2007). All patients received intravenous sodium bicarbonate 
prophylaxis. The primary endpoint was a post-dose serum creatinine increase of greater 
than 0.5 mL/dL over baseline. The renal effects of these two agents were comparable with 
no significant difference in occurrence of CIN and no significant difference in occurrence of 
CIN in the subgroup of chronic kidney disease patients with diabetes. More recently, a 
multicenter, randomized double-blind trial comparing the renal effects of non-ionic, iso-
osmolar iodixanol versus non-ionic, low-osmolar iopamidol in 526 patients with impaired 
baseline renal function and diabetes undergoing diagnostic and/or therapeutic coronary 
angiography procedures was completed (Laskey et al., 2009). This trial showed overall rate 
of CIN in patients with chronic kidney disease and diabetes undergoing coronary 
angiographic procedures was 10.5%. There was no significant difference between iodixanol 
and iopamidol in either peak increase in serum creatinine or risk of CIN.  
The renal effects of iodixanol and iopamidol are comparable in high-risk diabetic patients 
requiring contrast medium for diagnostic studies or intervention. The non-renal differences 
between these contrast agents should be considered when selecting an agent and when 
obtaining informed patient consent, however. Using a contrast medium with a higher iodine 
concentration per milliliter, such as iopamidol which has 370 mg/mL compared to iodixanol 
which has 320 mg/mL iodine content, may allow for a smaller volume to be used 
intravenously without sacrificing image quality. The higher iodine concentration of 
iopamidol may make complex plaques easier to appreciate during coronary angiography 
and intervention. Other considerations are that iodixanol is threefold more likely to cause 
contrast-induced delayed skin reactions compared to iopamidol. After percutaneous 
coronary intervention with bare-metal or drug-eluting stent placement, cardiac patients 
require antiplatelet therapy with clopidogrel, which may cause a rash within 5 to 7 days of 
treatment initiation, a timeline similar to that for delayed contrast-induced skin reactions. In 
clinical trials with clopidogrel, skin reactions are noted in 4.2% of patients. The choice of a 
contrast molecule, such as iopamidol, that is less likely to cause a delayed contrast-induced 
skin reaction makes decisions regarding the discontinuation of clopidogrel less frequent and 
more definitive. Finally, iopamidol is less expensive than iodixanol.  
Gadolinium-based contrast agents were introduced, partly, because of the discovery that 
iodine-based contrast medium could cause CIN. However, recent reports suggest that 
gadolinium-based agents may also be nephrotoxic. Furthermore, after exposure to 
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gadolinium-based contrast, some patients with renal insufficiency have developed 
nephrogenic systemic sclerosis with scleroderma-like changes in the skin, connective tissues 
and other organs, which has sometimes been fatal (Grobner & Prischl, 2007). In diabetic 
patients with chronic renal failure, the use of any contrast agent should be avoided, if 
possible, but, if required, small volumes of a contrast agent, such as iodixanol or iopamidol 
with proper hydration appears to be the safest clinical management to reduce renal and 
long-term patient risk. 
Ongoing investigation is searching for even more sensitive markers that may predict the 
development of CIN after percutaneous coronary interventions in patients with normal 
serum creatinine values (Kato et al., 2008). Future studies should include cystatin C which is 
an alternative serum measurement of kidney function that approximates direct measures of 
GFR more precisely than creatinine because its serum concentrations are independent of 
muscle mass and do not appear to be affected by age or sex. Cystatin C may identify a 
preclinical risk of kidney dysfunction after contrast medium that is not detected by serum 
creatinine or eGFR (Perkins et al., 2005). More recently, the value of neutrophil gelatinase-
associated lipocalin (NGAL) has been highlighted as a novel biomarker for the early 
detection of acute renal failure (Ling et al., 2008).  NGAL, a member of the lipocalin family, 
was originally isolated from the supernatant of activated human neutrophils, but it is also 
expressed at a low level in human tissues, including the kidney. Because of its small 
molecular size and resistance to degradation, NGAL is readily excreted and detected in 
urine. Thus, NGAL is highly accumulated in human kidney cortical tubules, blood and 
urine after renal injuries. NGAL might represent an early, sensitive and noninvasive urinary 
marker for the detection of CIN. Initial studies of NGAL after percutaneous coronary 
intervention showed an earlier increase in serum than in urine probably because NGAL was 
released into the circulation secondary to inflammatory activation of neutrophils initiated by 
percutaneous coronary intervention. Moreover, since NGAL is increased in atherosclerotic 
plaques, it might also be released in the circulation during the PCI. It has been found that 
predictors of serum NGAL 2 hours after PCI were serum creatinine, cystatin C, length of the 
percutaneous coronary intervention and the presence of diabetes. These findings have 
important implications for the clinical management of diabetic patients undergoing PCI. 
Since patients after PCI are often discharged the next day and CIN often occurs subsequent 
to discharge, NGAL needs to be investigated as a potential early marker for nephrotoxicity. 
Further studies in type 2 diabetes mellitus patients with chronic renal failure undergoing 
contrast medium administration are warranted to assess the use of NGAL with respect to 
earlier detection of CIN so that patients can be advised properly and medicines, such as 
metformin and angiotensin-converting enzyme inhibitors or angiotensin II receptor 
blockers, can be restarted appropriately.  
In patients undergoing cardiac catheterization, cystatin C may be useful in predicting before 
catheterization the risk of CIN. In contrast, urinary human liver-type fatty acid-binding 
protein (L-FABP) consistently appears to be the only marker for detecting transient renal 
tubular damage in patients with moderate renal disease. Thus, urinary L-FABP appears to 
be a useful marker of renal tubular damage caused by contrast medium. Other investigators 
have found that urinary intraleukin-18 (IL-18) is associated with the later cardiac outcomes 
in patients with CIN after coronary angiography. CIN, a form of acute kidney injury, has 
received increasing attention the past few years because of the recognition that CIN is 
associated with long-term adverse events. The increased incidence of adverse events after 
CIN is derived primarily from retrospective analysis of large data bases or observational 
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studies of patients who have undergone coronary angiography and/or percutaneous 
coronary intervention. A cause-and-effect relationship cannot be determined from such 
data. Patients with an increased burden of cardiovascular risk factors before contrast 
medium exposure may be more likely to develop CIN and independent of the occurrence of 
CIN may have more long-term adverse events (Shlipak et al., 2005). Alternatively, the 
occurrence of CIN may in some as yet undefined manner alter the future likelihood of 
adverse events (i.e., CIN triggers a pathophysiologic pathway that leads to adverse events). 
The Cardiac Angiography in REnally-impaired patients (CARE) study has allowed the 
opportunity to explore the association of CIN with long-term adverse events (Solomon et al., 
2009). Patients were followed for the year after the trial, and adverse events were collected. 
The rate of long-term adverse events was higher in individuals who developed CIN. After 
adjustment for baseline comorbidities and risk factors, the adjusted incident ratio for 
adverse events was twice as high in those with CIN compared to the patients who did not 
develop CIN. It is also noted that randomization to iopamidol reduced the incidence of CIN 
and adverse events compared to iodixanol. Parallel decrease of incidence of CIN and 
adverse events in the iopamidol arm of this randomized trial supports a causal role for CIN 
in late adverse events in diabetic patients undergoing coronary angiography and/or 
coronary intervention. Why a transient decrease in renal function results in long-term 
increased risk of cerebrovascular accident, myocardial infarction and death is an area of 
intense study. Some investigators report that traditional cardiovascular risk factors have 
greater associations with cardiovascular mortality than novel risk factors. Thus, in patients 
that develop CIN, continued treatment of hypertension, hyperlipidemia and diabetes is 
recommended. Since multiple studies have demonstrated the important role of nitric oxide 
in endothelial physiology and the pathogenesis of vascular disease, ongoing studies are 
examining endogenous nitric oxide synthase inhibitors, such as the amino acid asymmetric 
dimethylarginine, in the pathogenesis of late adverse events (Chirinos et al., 2008). 
Additional studies are required to assess the prognostic value of measuring for this 
endogenous nitric oxide synthase inhibitor and assessing whether interventions limiting its 
effect will benefit patients at risk for future cardiovascular events. 
2.1.1.1 Risks and benefits of prevention strategies to attenuate contrast-induced 
nephropathy in patients with type 2 diabetes mellitus and coronary artery disease 
The risks of a short course of theophylline, either orally or intravenously, is low. If a patient 
is on theophylline, one cannot give adenosine as a coronary vasodilator as part of a flow 
wire analysis to assess the functional significance of a coronary stenotic lesion (Casella et al., 
2003; Yoon et al., 2009). However, intravascular ultrasound can be used as the guide for 
functional significance, and, thus, pretreatment with theophylline to attenuate CIN may be 
more important than losing this one technique of assessing functional coronary stenosis. Of 
the various potential strategies for attenuating CIN, theophylline can be administered orally 
or intravenously within 30 minutes of the procedure and be beneficial. Antioxidant 
strategies, such as allopurinol, ascorbic acid, or N-acetylcysteine require pretreatment and 
will be less helpful in patients requiring emergency diagnostic and/or interventional 
contrast medium usage.  
Volume expansion with normal saline or sodium bicarbonate is the universally agreed upon 
strategy to attenuate CIN. Bicarbonate therapy was initially explored because the generation 
of oxygen-free radicals is pH dependent through the Haber-Weiss reaction (Merten et al., 
2004). Alkalinization of the urinary space is achieved very quickly with intravenous infusion 
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of sodium bicarbonate because normally there is little bicarbonate in the urine. Even a small 
increase in serum bicarbonate of 1 to 2 mEq/L will result in the ‘dumping’ of bicarbonate 
into the urine in most patients (Solomon, 2009). Such a change in serum is easily obtained 
with the infusion rate recommended.  Sodium bicarbonate therapy is readily available, 
inexpensive, and safe.  The question is whether it is efficacious for prevention of CIN. Of 
particular clinical interest from recent meta-analysis was the finding that sodium 
bicarbonate therapy is most effective in patients who experienced urgent or emergency 
contrast medium exposure (Meier et al., 2009).  Presumably this selects a group of patients 
who are less likely to receive any other form of prophylaxis for CIN.  This is of great 
potential importance for the emergency room and cardiac catheterization laboratory.  
Sodium bicarbonate therapy was also most effective in those receiving low osmolality 
contrast media compared with iso-osmolality contrast media.  Low osmolality contrast is 
increasingly chosen because of its safety, lower costs, and higher iodine content. It has also 
been found that the addition of N-acetylcysteine to fluid expansion with sodium bicarbonate 
showed no additional reduction in the rate of CIN after the intra-arterial administration of 
iopamidol or iodixanol to high-risk patients with type 2 diabetes mellitus and chronic 
kidney disease (Staniloae et al., 2009). 
CIN needs to be redefined using markers of kidney injury that are sensitive, specific, and 
predictive of adverse outcomes (Solomon, 2009).  This will enable investigators to better 
address the question of how to attenuate this condition in the future.  The most important 
question to be answered is whether prevention of kidney injury results in a change in short-
and long-term adverse outcomes.  Using iopamidol has been associated with a reduction in 
long-term adverse events (Solomon et al., 2007). The recent meta-analyses found that despite 
a reduction in the incidence of CIN, sodium bicarbonate therapy had no benefit on the need 
for dialysis or mortality (Meier et al., 2009).  No matter how available, inexpensive, and safe 
a potential preventive therapy, to find an important role in clinical therapeutics, it must 
improve the ‘downstream’ adverse outcomes, an as yet elusive goal for the prevention and 
treatment of CIN (Solomon, 2009).  
3. Conclusions 
In summary, CIN remains an important clinical challenge in patients with type 2 diabetes 
mellitus with coronary artery disease. Reducing the incidence of CIN requires recognizing 
high risk patients, such as patients with type 2 diabetes mellitus. Long-term risk factor 
modification should improve endothelial function so a more normal renal compensatory 
response will occur should contrast medium administration be required.  Lowest volume of 
iopamidol needed would appear to be the contrast agent of choice.  In patients with type 2 
diabetes mellitus, pretreatment with theophylline to block adenosine-mediated renal 
vasoconstriction combined with volume expansion with sodium bicarbonate to limit 
oxygen-free radical generation is a rational approach based on existing data. Appropriately 
designed robust randomized clinical trials combining pharmacologic approaches aimed at 
both the renal vasoconstriction and the oxygen-free radical generation are needed to confirm 
that this is the best preventive strategy in patients with type 2 diabetes mellitus.  
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